Sarepta Therapeutics, Inc.

Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) resulting from allegations that Sarepta may have issued materially misleading business information to the investing public.

If you purchased Sarepta securities and would like to join the prospective action, please click “Join This Class Action.”

If you purchased Sarepta securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Details of investigation:

On January 7, 2021, after market hours, Sarepta announced its gene therapy as a one-time treatment for the rare disorder Duchenne muscular dystrophy failed to show benefits compared with a placebo. Sarepta’s shares dropped almost 49.7%, or $83.95, from closing at $168.95 on January 7, 2021 to open at $85.00 on January 8, 2021.

Attorney Advertising. Prior results do not guarantee a similar outcome.

公司名称: Sarepta Therapeutics, Inc.
股票代号: SRPT
集体诉讼期: N/A
法院: N/A


自 2013 年以来,罗森律师事务所每年都是代表投资者成功提起证券集体诉讼的前四大律所之一。仅 2019 年,本律所就为投资者追回 4.38 亿美元资金。


机构股东服务公司按 2017 年证券集体诉讼索赔数量,罗森律师事务所列为第一名。